-
Mashup Score: 0In situ detection of PD1–PD-L1 interactions as a functional predictor for response to immune checkpoint inhibition in NSCLC. - 5 hour(s) ago
Immune checkpoint inhibitors (ICIs) have transformed lung cancer treatment, yet their effectiveness appears restricted to certain patient subsets. Current clinical stratification based on PD-L1 expression offers limited predictive value. Given the mechanism of action, directly detecting spatial PD1–PD-L1 interactions might yield more precise insights into immune responses and treatment outcomes.
Source: www.jto.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
Investigator-assigned Subjective or Judgmental Efficacy and Toxicity (ISJET) reporting represents language used to contextualize efficacy or toxicity data in clinical trials that may be inappropriate or misleading. In addition, pooling of grade 1 and 2 adverse events (AEs) may reflect a practice based on acute chemotherapy treatments rather than the expansion of chronic treatments that are now commonplace for many patients with lung cancer. In this study, we set out to evaluate the use of ISJETs and combined grade 1 and 2 reporting in early phase clinical trials of lung treatments at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
Source: www.jto.orgCategories: General Medicine News, Oncologists1Tweet-
After evaluating the use of ISJETs & toxicity reporting practices in early phase clinical trials of #lungcancer treatments at #ASCO24, the authors determined that initiatives to increase objective language & specificity in toxicity reporting are warranted. https://t.co/iqs7zQxEWj https://t.co/q9G6QpSFbV
-
-
Mashup Score: 10IASLC Reviewer Workshop | IASLC - 7 day(s) ago
Improving Reviewer Performance.
Source: www.iaslc.orgCategories: General Medicine News, Onc News and JournalsTweet-
The IASLC Reviewer Workshop is a 1 day workshop @ #WCLC24, led by leaders in the field, to train early/mid-career IASLC members in manuscript review. Application opens Feb. 1 to members in the Americas. Learn More: https://t.co/35X0oBzZd5 #LCSM @JTOonline https://t.co/mNKxpeWD7W
-
-
Mashup Score: 10IASLC Reviewer Workshop | IASLC - 8 day(s) ago
Improving Reviewer Performance.
Source: www.iaslc.orgCategories: General Medicine News, Onc News and JournalsTweet-
The IASLC Reviewer Workshop is a 1 day workshop @ #WCLC24, led by leaders in the field, to train early/mid-career IASLC members in manuscript review. Application opens Feb. 1 to members in the Americas. Learn More: https://t.co/35X0oBzZd5 #LCSM @JTOonline https://t.co/mNKxpeWD7W
-
-
Mashup Score: 18
The advocacy Women Against Lung Cancer in Europe (WALCE) promoted the European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA) and provided a free-of-charge molecular profiling platform for NSCLC sample characterization with the aim of increasing the detection of targetable drivers and improving patients’ access to clinical trials in Europe.
Source: www.jto.orgCategories: General Medicine News, Oncologists1Tweet-
Women Against Lung Cancer in Europe promoted EPROPA to reduce the gap between relevant heterogeneity of molecular testing & cancer care. This program aimed to improve patient access to clinical trials by providing free-of-charge molecular profiling. https://t.co/6yUR9Plbj9 #LCSM https://t.co/JEJtIAodz5
-
-
Mashup Score: 5A Perspective on the MARS2 Trial - 14 day(s) ago
The phase 3 randomized controlled trial of extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (PM) (MARS2) reported “extended pleurectomy decortication was associated with worse survival to 2 years, and more serious adverse events for individuals with resectable PM, compared with chemotherapy alone.” These results have led to considerable discourse regarding the future role of surgery for PM, and there has not been unanimity in the mesothelioma surgical community regarding the trial interpretation.
Source: www.jto.orgCategories: General Medicine News, Oncologists1Tweet-
Results from the MARS2 trial reported that pts who received extended pleurectomy decortication and chemotherapy had worse survival rates than those who received chemotherapy alone. The MARS2 results are controversial and the debate continues in JTO. https://t.co/LeCeEX8FTQ #LCSM https://t.co/Y4DmaqjLYj
-
-
Mashup Score: 10IASLC Reviewer Workshop | IASLC - 15 day(s) ago
Improving Reviewer Performance.
Source: www.iaslc.orgCategories: General Medicine News, Onc News and JournalsTweet-
The IASLC Reviewer Workshop is a 1 day workshop @ #WCLC24, led by leaders in the field, to train early/mid-career IASLC members in manuscript review. Application opens Feb. 1 to members in the Americas. Learn More: https://t.co/35X0oBzZd5 #LCSM @JTOonline https://t.co/mNKxpeWD7W
-
-
Mashup Score: 10IASLC Reviewer Workshop | IASLC - 15 day(s) ago
Improving Reviewer Performance.
Source: www.iaslc.orgCategories: General Medicine News, Onc News and JournalsTweet-
The IASLC Reviewer Workshop is a 1 day workshop @ #WCLC24, led by leaders in the field, to train early/mid-career IASLC members in manuscript review. Application opens Feb. 1 to members in the Americas. Learn More: https://t.co/35X0oBzZd5 #LCSM @JTOonline https://t.co/mNKxpeWD7W
-
-
Mashup Score: 5Screening for Lung Cancer, Overdiagnosis, and Healthcare Utilization: A Nationwide Population-Based Study - 1 month(s) ago
Guideline-discordant low-dose computed tomography (LDCT) screening may cause lung cancer (LC) overdiagnosis, but its extent and consequences are unclear. This study aimed to investigate the prevalence of self-initiated, non-reimbursed LDCT screening in a predominantly non-smoking population and its impact on LC epidemiology and healthcare utilization.
Source: www.jto.orgCategories: General Medicine News, Oncologists1Tweet-
This study aimed to investigate the prevalence of widespread guideline-discordant LDCT screening in a low-risk population. Read about its impact on LC epidemiology & healthcare utilization in this article by Kim SY et al: https://t.co/QuPC1sPcWP #LCSM https://t.co/6F2rMH7LtX
-
-
Mashup Score: 34
Poly (ADP-ribose) inhibitors, including olaparib, upregulate programmed cell death ligand 1 (PD-L1), which may increase efficacy of anti–PD-(L)1 therapies.
Source: www.jto.orgCategories: General Medicine News, Oncologists1Tweet-
The KEYLYNK-006 trial determined that pembrolizumab plus maintenance olaparib did not improve PFS or OS vs pembrolizumab plus pemetrexed in previously untreated metastatic nonsquamous #NSCLC. Read more about the trial here: https://t.co/dobOGhO1J5 #LCSM https://t.co/0gjgIOLlYG
-
This study proposes a diagnostic shift from static biomarker quantification in pts w/#NSCLC to assessing active immune pathways in order to provide more precise ICI treatment. Ultimately, the results implicate a need for combination diagnostics & therapies.https://t.co/2Vy8Y7JcM9 https://t.co/IwNtOkvesg